ArticleBMJ public health2025
Association between catastrophic health expenditure and mortality in older people in 11 European health systems: a longitudinal analysis between 2006 and 2020.
Article in BMJ public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Out-of-pocket expenditure (OOPE) and catastrophic health expenditure (CHE) challenge the financial protection provided by European health systems. Despite rising OOPE and CHE in Europe, evidence on health impact remains limited. This study examines the association between OOPE, CHE and all-cause mortality in older adults across 11 European countries from 2006 to 2020. Methods: We analysed longitudinal data from the Survey of Health, Ageing and Retirement in Europe, including 70 367 individuals aged ≥50 years across five waves (wave 2 (2006/2007), 5 (2013), 6 (2015), 7 (2017) and 8 (2019/2020)). CHE was defined as annual OOPE exceeding 25% of household income. Parametric survival models with Gompertz distribution estimated the association between CHE, OOPE and mortality, adjusting for socioeconomic and clinical covariates. Sensitivity analyses employed inverse probability weighting with regression adjustment. Results: Participants had a mean age of 65 years, 54% were women and 46% were retired. CHE was incurred by 1.6% of participants (range: 0.9%-2.2% by country). Over a mean follow-up of 3.8 years, 10.2% (7193) died. CHE was associated with an 84% increased mortality risk (95% CI 1.66 to 2.04), with the strongest effect in Switzerland (HR 4.22, 95% CI 2.54 to 7.00). Each €100 increase in total OOPE was associated with a 0.4% higher mortality risk (95% CI 1.002 to 1.006), especially in higher-income groups. OOPE on medicines showed heterogeneous effects: in the lowest income quintile, higher spending was associated with reduced mortality (HR 0.955, 95% CI 0.927 to 0.982), while in the third quintile (HR 1.044, 95% CI 1.017 to 1.071) and in countries like Czechia (HR 1.086, 95% CI 1.017 to 1.159) and Germany (HR 1.015, 95% CI 1.003 to 1.028), it was associated with increased mortality. Sensitivity analyses confirmed the main results. Conclusions: CHE and elevated OOPE are independently associated with increased mortality in older Europeans, suggesting negative long-term impacts on health. These findings underscore the need for cost-sharing reforms to preserve equity and protect vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.